Company intelligence / Profile preview

Nutriease

Hangzhou, Zhejiang, China

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Nutriease focuses on chronic disease management through nutritional interventions, particularly for obesity and metabolic syndrome. The company has participated in clinical research demonstrating that substituting peanuts for refined-grain snacks can improve metabolic syndrome risk without promoting weight gain among Chinese adults at high risk of cardiometabolic diseases. No significant changes were observed in glycemic or lipid parameters.

Therapeutic areas: Metabolic DisordersCardiovascularEndocrinology
Modalities: Non-pharmacological therapyNutritional intervention
Industry: Food & Nutrition

Partnerships

No major pharmaceutical or biotech partnerships identified; previously considered investment from Sinocare

Beyond the preview

Go deeper on Nutriease.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nutriease.

Explore the full profile